The imperatives of leprosy treatment in the pre‐ and post‐global leprosy elimination era: Appraisal of changing the scenario to current status

References

• Sasaki S., Takeshita F., Okuda K., Ishii N. Mycobacterium leprae and leprosy: A compendium. Microbiol Immunol 2001; 45: 729–36
   PubMed Web of Science ®Google Scholar
• Ishii N. Recent advances in the treatment of leprosy. Dermatol Online J 2003; 9: 5
   PubMedGoogle Scholar
• Anonymous. Draft resolution, sixth meeting of the WHO technical advisory group on elimination of leprosy (TAG). World Health Organization, Geneva February 2004
   Google Scholar
• Anonymous. WHO. World Health Assembly – Resolution WHA 44.9. World Health Organization, Geneva 1991
   Google Scholar
• Anonymous. Leprosy – global situation. Wkly Epidemiol Rec 2000; 75: 226–31
   PubMedGoogle Scholar
• Anonymous. Global leprosy situation. Wkly Epidemiol Rec 2006; 81: 309–16
   PubMedGoogle Scholar
• Anonymous. Global situation of leprosy control at the beginning of the 21st century. Report of the international leprosy association technical forum. Lepr Rev 2002; 73: S3–61
   PubMedGoogle Scholar
• Anonymous. WHO Expert Committee on Leprosy. Seventh Report. World Health Organization, Geneva 1998, (WHO Technical Report Series 874)
   Google Scholar
• Sehgal V. N. Clinical leprosy. Illustrated 4th ed. Jaypee Brothers, New Delhi 2004; 24–7
   Google Scholar
• Sehgal V. N., Joginder. Slit‐skinsmear in leprosy. Int J Dermatol 1990; 29: 9–16
   PubMedGoogle Scholar
• Lockwood D. N. Leprosy elimination – A virtual phenomenon or a reality?. BMJ 2002; 324: 1516–18
   PubMed Web of Science ®Google Scholar
• Ishii N., Sugita Y., Sato I., Nakajima H. Sparfloxacin in the treatment of leprosy patients. Int J Dermatol 1997; 36: 619–21
   PubMedGoogle Scholar
• Anonymous. WHO model prescribing information: Drugs used in leprosy. World Health Organization, Geneva 1998, (WHO/DMP/DSI/98.1)
   Google Scholar
• Anonymous. Chemotherapy of leprosy for control programmes. World Health Organization, Geneva 1982, (WHO Technical Report Series 675)
   Google Scholar
• Anonymous. The final push strategy to eliminate leprosy as a public health problem. Questions and answers. World Health Organization, Geneva 2003, 2nd ed
   Google Scholar
• Anonymous. Chemotherapy of leprosy. Report of a WHO study group. World Health Organization, Geneva 1994, (WHO Technical Report Series 847)
   Google Scholar
• Anonymous. A guide to eliminating leprosy as a public health problem. 1st ed. WHO/LEP/95.1. World Health Organization, Geneva 1995
   Google Scholar
• Sugita Y., Suga C., Ishii N., Nakajima H. A case of relapsed leprosy successfully treated with sparfloxacin. Arch Dermatol 1996; 132: 1397–8
   PubMedGoogle Scholar
• Jacobson R. R. Treatment of leprosy. Leprosy. 2nd ed, R. C Hastings. Churchill Livingstone, London 1994; 317–49
   Google Scholar
• Ahmad R. A., Rogers H. J. Plasma and salivary pharmacokinetics of dapsone estimated by a thin layer chromatographic method. Eur J Clin. Pharmacol 1980; 17: 129–33
   PubMedGoogle Scholar
• Schaad‐Lanyi Z., Dieterle W., Dubois J. P., Theobald W., Vischer W. Pharmacokinetics of clofazimine in healthy volunteers. Int J Lepr Other Mycobact Dis 1987; 55: 9–15
   PubMedGoogle Scholar
• Morrison N. E., Marley G. M. Clofazimine binding studies with deoxyribonucleic acid. Int J Lepr Other Mycobact Dis 1976; 44: 475–81
   PubMedGoogle Scholar
• Ji B. Prospects for chemotherapy of leprosy. Indian J Lepr 2000; 72: 187–98
   PubMedGoogle Scholar
• Ji B., Grosset J. Combination of rifapentine‐moxifloxacin‐minocycline (PMM) for the treatment of leprosy. Lepr Rev 2000; 71: S81–7
   PubMedGoogle Scholar
• Anonymous, What is thalidomide? TVAC: Thalidomide Victims Association of Canada. September 01, 1999. URL: http://www.thalidomide.ca
   Google Scholar
• James JS. (ATN) Thalidomide and HIV: Background. AIDS Treatment News Issue #179. July 23, 1993. URL: http://www.aegis.com/pubs/atn/1993/ATN17902.html
   Google Scholar
• Lenz W. The history of thalidomide. TVAC: Thalidomide Victims Association of Canada. September 01, 1999. URL: http://www.thalidomide.ca
   Google Scholar
• Pannikar V. The return of thalidomide: New uses are renewed concerns. 2003, WHO Pharmaceuticals Newsletter, No. 2
   Google Scholar
• Dharmendra. Leprosy. Vol. 1. Kothari Medical Publishing House, Bombay 1978
   Google Scholar
• Browne S. G. ‘B 663’ possible anti‐inflammatory action in lepromatous leprosy. Lepr Rev 1965; 36: 9–11
   PubMedGoogle Scholar
• Ramu G., Iyer C. G. Treatment of reactions in leprosy. A window on leprosy, B. R Chatterjee. Gandhi Memorial Leprosy Foundation, Wardha 1978
   Google Scholar
• Browne S. G. ‘B 663’ possible anti‐inflammatory action in lepromatous leprosy. Lepr Rev 1965; 36: 9–11
   PubMedGoogle Scholar
• Iyer C. G., Languillon J., Ramanujam K., Tarabini‐Castellani G., De las Aguas J. T., Bechelli L. M., et al. WHO co‐ordinated short‐term double‐blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Organ 1971; 45: 719–32
   PubMed Web of Science ®Google Scholar
• Iyer C. G., Ramu G. An open trial with clofazimine in the management of recurrent lepra reaction using thalidomide as a control drug. Lepr India 1976; 48: 690–4
   PubMedGoogle Scholar
• Becx‐Bluemink M., Berhe D. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; Experience in the Leprosy Control Program of All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Int J Lepr Other Mycobact Dis 1992; 60: 173–84
   PubMedGoogle Scholar
• Perri A. J 3rd., Hsu S. A review of thalidomide's history and current dermatological applications. Dermatol Online J 2003; 9: 5
   PubMedGoogle Scholar
• Sehgal V. N., Sardana K. Lepra vaccine. Skinmed 2004; 3: 167–8
   PubMedGoogle Scholar
• Sehgal V. N., Sardana K. Lepra vaccine: Misinterpreted myth. Int J Dermatol 2006; 45: 164–7
   PubMedGoogle Scholar
• Kar P. K., Arora P. N., Ramasastry C. V., Dhaka R. S. A clinicopathological study of multidrug therapy in borderline tuberculoid leprosy. J Indian Med Assoc 1994; 92: 336–7
   PubMedGoogle Scholar
• Boerrigter G., Ponnighaus J. M., Fine P. E. Preliminary appraisal of a WHO‐recommended multiple drug regimen in paucibacillary leprosy patients in Malawi. Int J Lepr Other Mycobact Dis 1988; 56: 408–17
   PubMedGoogle Scholar
• Dasananjali K., Schreuder P. A., Pirayavaraporn C. A study on the effectiveness and safety of the WHO/MDT regimen in the northeast of Thailand; a prospective study, 1984–1996. Int J Lepr Other Mycobact Dis 1997; 65: 28–36
   PubMedGoogle Scholar
• Gebre S., Saunderson P., Byass P. Relapse after fixed‐duration multiple drug therapy: The AMFES cohort. Lepr Rev 2000; 71: 325–31
   PubMedGoogle Scholar
• Boerrigter G., Ponnighaus J. M., Fine P. E., Wilson R. J. Four‐year follow‐up results of a WHO‐recommended multipledrug regimen in paucibacillary leprosy patients in Malawi. Int J Lepr Other Mycobact Dis 1991; 59: 255–61
   PubMedGoogle Scholar
• Schreuder P. A. The occurrence of reactions and impairments in leprosy: Experience in the leprosy control program of three provinces in northeastern Thailand, 1987–1995 [correction of 1978–1995]. I. Overview of the study. Int J Lepr Other Mycobact Dis 1998; 66: 149–58
   PubMedGoogle Scholar
• Shetty V. P., Wakade A. V., Ghate S., Ganapati R., Antia N. H., Pai V. V. Viability and drug susceptibility testing of M. leprae using mouse footpad in 37 relapse cases of leprosy. Int J Lepr Other Mycobact Dis 2003; 71: 210–17
   PubMedGoogle Scholar
• Li H. Y., Hu L. F., Huang W. B., Liu G. C., Yuan L. C., Jin Z., et al. Risk of relapse in leprosy after fixed‐duration multidrug therapy. Int J Lepr Other Mycobact Dis 1997; 65: 238–45
   PubMedGoogle Scholar
• Ji B. H. Drug resistance in leprosy – a review. Lepr Rev 1985; 56: 265–78
   PubMedGoogle Scholar
• Katoch K. Therapeutic prospects for paucibacillary leprosy. Indian J Lepr 2000; 72: 351–61
   PubMedGoogle Scholar
• Girdhar B. K., Girdhar D. A. Short course treatment of leprosy: Present status. Icmr Bull 2002; vol. 32(no. 2)
   Google Scholar
• Katoch K., Ramanathan U., Natrajan M., Bagga A. K., Bhatia A. S., Saxena R. K., et al. Relapses in paucibacillary patients after treatment with three short‐term regimens containing rifampin. Int J Lepr Other Mycobact Dis 1989; 57: 458–64
   PubMedGoogle Scholar
• Bhate R. D., Gupta C. M., Chattopadhyay S. P., Singh I. P. Experience with multidrug therapy in paucibacillary leprosy. Indian J Lepr 1986; 58: 244–50
   PubMedGoogle Scholar
• Efficacy of single‐dose multidrug therapy for the treatment of single‐lesion paucibacillary leprosy. Single‐lesion Multicentre Trial Group., Indian J Lepr. 69. 121–9
   Google Scholar
• Pattyn S. R., Ghys P., Janssens L., Tshilumba K., Kuykens L., Karibushi N., et al. A randomized clinical trial of two single‐dose treatments for paucibacillary leprosy. Lepr Rev 1994; 65: 45–57
   PubMedGoogle Scholar
• Girdhar B. K., Girdhar A., Kumar A. Relapses in multibacillary leprosy patients: Effect of length of therapy. Lepr Rev 2000; 71: 144–53
   PubMedGoogle Scholar
• Shaw I. N., Natrajan M. M., Rao G. S., Jesudasan K., Christian M., Kavitha M. Long‐term follow up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed‐duration of two years. Int J Lepr Other Mycobact Dis 2000; 68: 405–9
   PubMedGoogle Scholar
• Yawalkar S. J., McDougall A. C., Languillon J., Ghosh S., Hajra S. K., Opromolla D. V., et al. Once‐monthly rifampicin plus daily dapsone in initial treatment of lepromatous leprosy. Lancet 1982; i: 1199–202
   Google Scholar
• Daumerie D. Current World Health Organization‐sponsored studies in the chemotherapy of leprosy. Lepr Rev 2000; 71: S88–90
   PubMedGoogle Scholar